At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating DC-806 and Placebo for Plaque Psoriasis. Completed, enrolled 229 participants across 56 sites in 8 countries.
Detailed Summary
This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.
Study Details
Timeline
Interventions
DC-806 was supplied as tablets to be administered orally.
Matching placebo was supplied as tablets to be administered orally.